In this proposal we will establish The Johns Hopkins PKD Research and Clinical Core Center (JH-PKD Center), which will provide unique resources and expertise to a national and international Research Base. The Center capitalizes on a long tradition of PKD research at Johns Hopkins and on our unique status as a comprehensive PKD center. The goals of the center are 1) To provide state of the art reagents and expertise to a national and international group of investigators in order to facilitate PKD related research, 2) To provide reagents and expertise to non-PKD investigators in order to remove barriers to PKD related research, 3) To continue to support a vibrant PKD research community that will lead to collaborative interactions between investigators, 4) To establish enrichment activities that encourage open and critical thought and yield creative approaches to research questions, 5) To provide Pilot and Feasibility Funds to junior investigators, to support innovative lines of inquiry and to recruit new expertise to the PKD field and 6) To partner with other PKD Centers and the NIDDK to ensure that resources are used efficiently with a goal of stimulating Translational PKD Research. The JH-PKD Center will contain an Administrative Core (Core A) and 4 biomedical core resources including 1) Antibody Validation and Vectorology (Core B), 2) Mouse models and Biobank (Core C) 3) Cell Engineering (Core D) and 4) the Clinical and Translational Core Resource (Core E). Pilot studies chosen for the first year are tightly focused around Core resources and recruit 3 new investigators at different career stages to the PKD field. Pilot 1 will examine Racial Disparities in Attitudes towards Screening, Treatment, and Participation in Clinical Research for PKD. Pilot 2 will apply cutting edge molecular tools for live cell imaging to examine the role of polycystin 1 and 2 in renal tubuologenesis. Pilot 3 proposes to test a novel glycolipid Inhibitor using the animal models and expertise provided by Core C. Through expanded interdisciplinary science collaborations, we hope to catalyze the translation of biomedical discoveries that slow down or prevent progression of polycystic kidney disease and its consequences. Public Health Relevance: The Polycystic Kidney diseases are a common group of disorders that are a leading cause of end stage renal disease. Despite many advances over the past several years, there is still no cure. We expect that this Core Center will provide the tools and expertise to facilitate collaborative PKD research leading to enhanced understanding of disease pathogenesis and innovative therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
1P30DK090868-01
Application #
8049452
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O1))
Program Officer
Flessner, Michael Francis
Project Start
2010-09-30
Project End
2015-06-30
Budget Start
2010-09-30
Budget End
2011-06-30
Support Year
1
Fiscal Year
2010
Total Cost
$1,200,690
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Cai, Jing; Song, Xuewen; Wang, Wei et al. (2018) A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev 32:781-793
Seliger, Stephen L; Abebe, Kaleab Z; Hallows, Kenneth R et al. (2018) A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol 47:352-360
Lin, Cheng-Chao; Kurashige, Mahiro; Liu, Yi et al. (2018) A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci Rep 8:2743
Parnell, Stephen C; Magenheimer, Brenda S; Maser, Robin L et al. (2018) A mutation affecting polycystin-1 mediated heterotrimeric G-protein signaling causes PKD. Hum Mol Genet 27:3313-3324
Podrini, Christine; Rowe, Isaline; Pagliarini, Roberto et al. (2018) Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun Biol 1:194
Palygin, Oleg; Ilatovskaya, Daria V; Levchenko, Vladislav et al. (2018) Characterization of purinergic receptor expression in ARPKD cystic epithelia. Purinergic Signal 14:485-497
He, Kai; Ma, Xiaoyu; Xu, Tao et al. (2018) Axoneme polyglutamylation regulated by Joubert syndrome protein ARL13B controls ciliary targeting of signaling molecules. Nat Commun 9:3310
Bulley, Simon; Fernández-Peña, Carlos; Hasan, Raquibul et al. (2018) Arterial smooth muscle cell PKD2 (TRPP1) channels regulate systemic blood pressure. Elife 7:
Dalagiorgou, Georgia; Piperi, Christina; Adamopoulos, Christos et al. (2017) Mechanosensor polycystin-1 potentiates differentiation of human osteoblastic cells by upregulating Runx2 expression via induction of JAK2/STAT3 signaling axis. Cell Mol Life Sci 74:921-936
Kleene, Steven J; Kleene, Nancy K (2017) The native TRPP2-dependent channel of murine renal primary cilia. Am J Physiol Renal Physiol 312:F96-F108

Showing the most recent 10 out of 78 publications